NEW YORK, Feb. 07, 2022 — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that the Company has appointed Anthony Dias as its new Vice President of Finance.
Mr. Dias brings over 20 years of experience leading finance and operational teams at pharmaceutical, medical device and technology companies. Mr. Dias will oversee all financial aspects of the company, including financial planning and analysis, financial reporting, accounting and control, tax, and treasury. He will report directly to the Company’s CEO, Gerard Michel.
“Delcath is pleased to welcome Tony as the new V.P. of Finance,” said Gerard Michel, Chief Executive Officer. “Tony’s senior finance expertise, experience at leading healthcare organizations, and track record of success will be a great asset, as we focus on commercialization and expanding into new indications.”
Prior to Delcath, Anthony was the VP of Finance and Controller for Advanced Group and PAREXEL, a public company CRO, helping the sale of the company to private equity for $5.5 billion. Mr. Dias was also the Senior Vice President and Chief Financial Officer of SeaChange a public traded company providing video solutions and VP Finance of LeMaitre Vascular, a medical device manufacturer, where he helped lead the company’s Initial Public Offering in 2006. Mr. Dias is a certified public accountant and worked at Arthur Andersen, a multinational professional services firm.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
In connection with the appointment, Delcath has granted an equity award to Mr. Anthony Dias, Delcath’s Vice President of Finance, outside of the Company’s Amended and Restated 2020 Stock Incentive Plan and material to Mr. Dias’ acceptance of employment with the company.
Mr. Dias received options to purchase 30,000 shares of Delcath common stock. The options will be issued upon the employee’s grant date of February 7, 2022 (“Grant Date”), and all stock options included within the equity inducement award will have an exercise price equal to the closing price of Delcath common stock on the Grant Date. One-third of the options will vest on the first anniversary of the Grant Date with the remaining two thirds (20,000) of the options vesting in equal monthly installments over the 24-month period beginning on the first anniversary of the employment commencement date for Mr. Dias (1/24th will vest on the first day of each month during said 24-month period, provided that Mr. Dias remains employed as of each such vesting date). The options have a ten-year term.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).
In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.
Contact:
Delcath Investor Relations
Email: investorrelations@delcath.com
Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com
